福莫特罗联合布地奈德治疗支气管哮喘-慢性阻塞性肺疾病重叠综合征的远期疗效观察

Observation on Long-term Efficacy of Formoterol Combined with Budesonide in Treatment of Overlap Syndrome of Bronchial Asthma-Chronic Obstructive Pulmonary Disease

目的:探讨福莫特罗联合布地奈德治疗支气管哮喘-慢性阻塞性肺疾病重叠综合征的远期疗效。方法:选取2015年6月—2017年9月肇庆市第一人民医院收治的支气管哮喘-慢性阻塞性肺疾病重叠综合征患者75例,根据随机双盲法分为观察组45例和对照组30例。对照组患者给予布地奈德吸入剂,观察组患者给予布地奈德吸入剂联合福莫特罗吸入剂,两组患者均连续治疗1年,停药后随访1年。对比观察两组患者治疗前后第1 s用力呼气容积(FEV_1)、FEV_1占用力肺活量百分比(FEV_1/FVC)、气道阻力、气道传导率、哮喘控制测试评分及慢性阻塞性肺疾病症状评分的差异。结果:治疗前和治疗6个月时,两组患者肺功能指标的差异无统计学意义(P>0.05);治疗12个月后,观察组患者的FEV_1和FEV_1/FVC明显优于对照组,差异均有统计学意义(P<0.05);治疗6、12个月后,两组患者气道阻力和气道传导率均较治疗前明显改善,且观察组患者明显优于对照组,差异均有统计学意义(P<0.05);治疗6个月、12个月后,观察组患者哮喘控制测试评分明显高于对照组,差异均有统计学意义(P<0.05);治疗12个月后,观察组患者慢性阻塞性肺疾病症状评分明显低于对照组,差异有统计学意义(P<0.05)。结论:长期吸入布地奈德联合福莫特罗可有效改善患者的气道阻力和呼吸功能,使疾病长期处于稳定状态,降低急性加重反应的发作次数。

OBJECTIVE： To probe into the long-term efficacy of formoterol combined with budesonide in treatment of overlap syndrome of bronchial asthma-chronic obstructive pulmonary disease. METHODS： 75 patients with overlap syndrome of bronchial asthma-chronic obstructive pulmonary disease admitted into the First People＇ s Hospital of Zhaoqing from Jun. 2015 to Sept. 2017 were selected and divided into observation group （45 cases） and control group （30 cases ） via random double blind method. The control group was treated with budesonid inhalant, while the observation group was given budesonide inhalant combined with formoterol inhalant, both groups were treated for 1 year and followed-up for l year. Differences in FEV1, FEVJFVC, airway resistance, airway conductance, asthma control test （ACT） scores and symptom scores of COPD between two groups before and after treatment were compared and observed. RESULTS ： Before treatment and at 6 months after treatment, there was no statistical significance in difference of indices of pulmonary function （P 〉 0. 05） ; at 12 months after treatment, the FEV1 and FEV,/FVC of observation group were significantly better than those of the control group, with statistically significant differences （P 〈 0. 05） ; at 6 months and 12 months after treatment, the airway resistance and airway conductance of both groups had been significantly improved, and those of the observation group were significantly better than the control group, with statistically significant differences （P 〈0. 05） ; at 6 months and 12 months after treatment, the ACT score of observation group was significantly higher that of the control group, with statistically significant difference （P 〈0. 05） ; at 12 months after treatment, the symptom score of COPD of observation group was significantly lower than that of the control group, with statistically significant difference （P 〈 0. 05 ）. CONCLUSIONS： Long-term inhalation of budesonide combined with formoterol can effectively improve airway resistance and respiratory function, stabilize the illness state and reduce the frequency of acute exacerbation.